OncoMatch/Clinical Trials/NCT05407519
A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
Is NCT05407519 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Tislelizumab + Sitravatinib for hepatocellular carcinoma.
Treatment: Tislelizumab + Sitravatinib — This is an open label, multi-center, single arm study to evaluate the efficacy and safety of tislelizumab combined with sitravatinib as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of recurrence after curative resection.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: curative resection
Subjects who have undergone a curative resection
Cannot have received: systemic therapy
No previous systematic treatment
Cannot have received: locoregional therapy
No previous...locoregional therapy for HCC
Lab requirements
Liver function
child-pugh score, class a
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05407519 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages